       Document 0294
 DOCN  M9620294
 TI    Cytomegalovirus retinitis in patients with AIDS: current status.
 DT    9602
 AU    Luckie AP; Department of Ophthalmology, University of Melbourne, VIC.
 SO    Med J Aust. 1995 Nov 6;163(9):489-92. Unique Identifier : AIDSLINE
       MED/96085000
 AB    About 20%-30% of patients with AIDS will develop cytomegalovirus (CMV)
       retinitis when they are severely immunodeficient (CD4 cell count below
       40 cells/microL). It causes extensive retinal damage with visual
       deficits, and relapses are frequent. Intravenous ganciclovir and
       foscarnet are standard therapy, but their high toxicity and long term
       intravenous access mean that advances in treatment, including oral
       prophylactic agents, intravitreal injections and surgical implants, may
       provide a better quality of life for patients. Prophylactic
       ophthalmological screening of patients with CD4 cell counts below 100
       cells/microL to detect asymptomatic retinitis is needed.
 DE    Antiviral Agents/THERAPEUTIC USE  *AIDS-Related Opportunistic
       Infections/DIAGNOSIS/DRUG THERAPY  *Cytomegalovirus
       Retinitis/DIAGNOSIS/DRUG THERAPY  Foscarnet/THERAPEUTIC USE
       Ganciclovir/THERAPEUTIC USE  Human  JOURNAL ARTICLE  REVIEW  REVIEW,
       ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

